This is a Validated Antibody Database (VAD) review about human EFEMP1, based on 3 published articles (read how Labome selects the articles), using EFEMP1 antibody in all methods. It is aimed to help Labome visitors find the most suited EFEMP1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
EFEMP1 synonym: DHRD; DRAD; FBLN3; FBNL; FIBL-3; MLVT; MTLV; S1-5; EGF-containing fibulin-like extracellular matrix protein 1; EGF containing fibulin like extracellular matrix protein 1; extracellular protein S1-5; fibulin-3

Santa Cruz Biotechnology
mouse monoclonal (C-3)
  • western blot; human; loading ...; fig s9c
Santa Cruz Biotechnology EFEMP1 antibody (Santa Cruz, SC-365224) was used in western blot on human samples (fig s9c). Oncotarget (2016) ncbi
mouse monoclonal (mab3-5)
  • immunohistochemistry; human; 1:250; fig 3
Santa Cruz Biotechnology EFEMP1 antibody (Santa Cruz, sc-33722) was used in immunohistochemistry on human samples at 1:250 (fig 3). J Cancer Res Clin Oncol (2016) ncbi
Invitrogen
rabbit polyclonal
  • western blot; human; loading ...; fig 1
In order to suggest that fibulin-3 and stathmin overexpression is associated with the malignant transformation of mesothelial cells following exposure to asbestos-like fibers, Invitrogen EFEMP1 antibody (Thermo Fisher, PA5-26104) was used in western blot on human samples (fig 1). Oncol Lett (2016) ncbi
Articles Reviewed
  1. Rapisarda V, Salemi R, Marconi A, Loreto C, Graziano A, Cardile V, et al. Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells. Oncol Lett. 2016;12:3363-3367 pubmed
  2. Kwak J, Lee N, Lee H, Hong I, Nam J. HIF2?/EFEMP1 cascade mediates hypoxic effects on breast cancer stem cell hierarchy. Oncotarget. 2016;7:43518-43533 pubmed publisher
  3. Yoshida K, Nagasaka T, Umeda Y, Tanaka T, Kimura K, Taniguchi F, et al. Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms. J Cancer Res Clin Oncol. 2016;142:1557-69 pubmed publisher